Miraqules Introduces Groundbreaking Blood Clotting Nanotechnology
Bengaluru-based biotech startup Miraqules is set to unveil a revolutionary blood clotting technology at TechCrunch Disrupt 2025 in San Francisco. The company’s pioneering nanotechnology powder mimics natural blood clotting proteins to rapidly and effectively stop bleeding, potentially transforming trauma care worldwide. Co-founder and CEO Sabir Hossain, driven by a personal connection to the urgent need for improved clotting solutions, developed this innovation after a near-fatal accident involving his father years earlier.Innovative Nanotechnology Mimics Natural Clotting
Miraqules’ product is a powdered nanomaterial that, upon application, rapidly generates fibrous compounds at room temperature. These compounds absorb blood swiftly, facilitating clot formation within one to two minutes.“This is a product that will give you feedback instantly. If there is a person bleeding, you apply it, and the bleeding stops. This whole thing happens within one or two minutes,” said Sabir Hossain.Serendipitous Discovery Leads to Breakthrough
The technology’s inception was accidental. While working in a biomedical engineering lab, Hossain struggled to synthesize a material intended for bone tissue growth. The dismantled particles, when powdered and tested with a team researching blood clotting, demonstrated rapid clotting ability, sparking further innovation. Hossain explained, “It clotted the whole blood within maybe five to 10 seconds. We then developed a novel process combining off-the-shelf materials into a nanomaterial that mimics blood clotting proteins.”Rapid Development and Intellectual Property Protection
Partnering with childhood friend Mubeen Midda, Hossain advanced the technology from lab concept to market-ready product, securing 11 patents across seven countries including India, the U.S., and Israel.Pilot Programs Underway and Regulatory Approvals Imminent
Currently, Miraqules’ clotting powder is being piloted in a trauma care center in India, with regulatory clearance expected imminently. The company is also on track for U.S. Food and Drug Administration approval in 2026 following proactive engagement through the FDA’s pre-submission process. The startup has achieved these milestones with under $700,000 in funding, primarily from grants, underscoring the efficiency of its development strategy.Growing Market Interest and Strategic Partnerships
Miraqules has attracted interest from multiple hospital chains in India and the Israeli Defense Forces, signaling strong demand for effective hemostatic solutions in both civilian and military settings.FinOracleAI — Market View
Miraqules’ innovative nanotechnology represents a significant advancement in trauma care, addressing a critical need for rapid and reliable blood clotting solutions. The company’s lean capital utilization and strategic patenting provide a strong foundation for growth.- Opportunities: Expanding trauma care markets globally; partnerships with military and hospital systems; expedited regulatory approvals through early FDA engagement.
- Risks: Regulatory delays or hurdles in key markets; competition from established hemostatic products; scaling manufacturing and distribution effectively.
Impact: Miraqules is poised to disrupt the blood clotting market with its nanotech powder, potentially saving lives and creating new standards in emergency medical treatment.
Contents
Miraqules Introduces Groundbreaking Blood Clotting NanotechnologyInnovative Nanotechnology Mimics Natural ClottingSerendipitous Discovery Leads to BreakthroughRapid Development and Intellectual Property ProtectionPilot Programs Underway and Regulatory Approvals ImminentGrowing Market Interest and Strategic PartnershipsFinOracleAI — Market View
